目的:观察Toric人工晶状体植入用于治疗合并角膜散光的白内障患者的临床治疗效果。方法:对41例47眼合并角膜散光的白内障患者行超声乳化白内障吸出及人工晶状体植入术治疗,进行回顾性分析。其中22眼植入Toric人工晶状体,25眼植入AcrySof IQ人工晶状体。术后随访6mo,分析不同时间点裸眼视力、术后残余散光、并发症等,比较两种人工晶状体的疗效。观察Toric人工晶状体植入后的稳定性。结果:术后随访观察6mo,植入Toric人工晶状体的实验组,术后裸眼视力平均0.73±0.37,明显优于植入AcrySof IQ人工晶状体的对照组平均0.47±0.18,结果有显著性差异。实验组患者术后残余散光0.53±0.40D,明显低于对照组2.13±0.76D,差异有统计学意义。植入Toric人工晶状体组,随访6mo内视力稳定,人工晶状体位置稳定,术后平均旋转4.22±1.46°。结论:对于合并角膜散光的白内障患者,行白内障超声乳化吸出联合Toric人工晶状体植入,能够安全、有效的改善患者的散光,提高术后视觉质量,预测性好。

AIM:To evaluate toric intraocular lens (IOL) implantation as a treatment of regular corneal astigmatism during phacoemulsification.METHODS:Totally 41 cases(47 eyes) with cataract and corneal astigmatism had toric IOL(22 eyes) or spherical IOL(25 eyes) implantation during phacoemulsification, followed up for 6 months. Uncorrected distance visual acuity (UDVA), postoperative residual astigmatism, complications were analyzed, and effect of two IOLs were compared. Toric IOL axis rotational stability was observedRESULTS:Six months postoperatively, the mean UDVA was 0.73±0.37 in the toric IOL group and 0.47±0.18 in the spherical IOL group, there was statistical significant difference. The postoperative residual astigmatism was 0.53±0.40D in the Toric IOL group and 2.13±0.76D in the spherical IOL group, there was statistical significant difference. The visual acuity and the IOL location of Toric IOL group were both steady. The mean IOL misalignment was 4.22±1.46 degrees.CONCLUSION:Phacoemulsification combined with Toric IOL implantation for cataract and corneal astigmatism patients is effective, predictable and safe in correcting corneal astigmatism.

武汉市卫生局科研基金资助项目（武卫[2009]76号No.WX09C03）